[Skip to Navigation]
JAMA Network Home
Sign In

Year

Day

March 23, 2023
Original Investigation

Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer:The Phase 2b NIFTY Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0016

这个随机临床试验检查addition of treatment with liposomal irinotecan to fluorouracil and leucovorin for patients with advanced biliary tract cancer.

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer:A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0089

This randomized clinical trial compares exemestane, 25 mg, given once daily, 3 times weekly, and once weekly for the treatment of estrogen receptor–positive breast cancer in postmenopausal women prior to surgery.

Research Letter

Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0068

This cohort study investigates clinicopathologic and prognostic associations of hypercalcemia in patients with intrahepatic or extrahepatic cholangiocarcinoma.

Subcutaneous vs Intravenous Administration of Medications and Fluids for Patients With Cancer in the US and Canada

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0239

This cross-sectional study compares rates of subcutaneous and intravenous administration of medications and fluids among patients with cancer in 2 acute palliative care units in the US and Canada.

Editorial

JAMA Oncology—The Year in Review, 2022

Abstract Full Text
free access
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0235

An Oncology Artificial Intelligence Fact Sheet for Cancer Clinicians

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0012
Invited Commentary

Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0085
Comment & Response

FLASH Radiotherapy in a Value-Based Health Care Environment

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0131

FLASH Radiotherapy in a Value-Based Health Care Environment—Reply

Abstract Full Text
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0134
Peer Reviewers List

JAMA OncologyPeer Reviewers in 2022

Abstract Full Text
free access
JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0220
March 16, 2023
Original Investigation

每周紫杉醇+参观的临床疗效和安全性usertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma:The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online March 16, 2023. doi:10.1001/jamaoncol.2022.7966

This phase 2 randomized clinical trial evaluates whether the addition of vistusertib to weekly paclitaxel improves clinical outcomes in patients with platinum-resistant ovarian high-grade serous carcinoma.

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma:A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online March 16, 2023. doi:10.1001/jamaoncol.2022.7975

This nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed or refractory Hodgkin lymphoma.

JAMA Oncology Clinical Challenge

Left Axilla Adenocarcinoma of Unknown Origin

Abstract Full Text
has active quiz
JAMA Oncol. Published online March 16, 2023. doi:10.1001/jamaoncol.2022.7858

A 76-year-old woman presents with a palpable left axillary mass, yet no breast lesions are found. What is your diagnosis?

Comment & Response

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. Published online March 16, 2023. doi:10.1001/jamaoncol.2023.0108

High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply

Abstract Full Text
JAMA Oncol. Published online March 16, 2023. doi:10.1001/jamaoncol.2023.0111
March 9, 2023
Original Investigation

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy:A Phase 1 Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2022.7845

This nonrandomized clinical trial assesses the recommended phase 2 dose of regorafenib, ipilimumab, and nivolumab immunotherapy for patients with refractory microsatellite stable metastatic colorectal cancer.

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer:阶段2 TBCRC041随机临床试验

Abstract Full Text
open access
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2022.7949

This randomized clinical trial examines the effect of adding fulvestrant to alisertib on objective tumor response rates in endocrine-resistant metastatic breast cancer.

Viewpoint

Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers

Abstract Full Text
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2022.7842

This Viewpoint discusses the role of data interpretation and clinical trial design in improving therapy of neuroendocrine cancers.

Editorial

Immunotherapy Success for Microsatellite Stable Colorectal Cancers—Searching for the Horizon

Abstract Full Text
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2022.7786
Comment & Response

Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events

Abstract Full Text
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2023.0100

Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply

Abstract Full Text
JAMA Oncol. Published online March 9, 2023. doi:10.1001/jamaoncol.2023.0103
March 2, 2023
Original Investigation

First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer:A Living Systematic Review and Network Meta-analysis

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2022.7762

This systematic review meta-analysis investigates the comparative effectiveness of triplet therapy vs androgen pathway inhibitors doublet therapy for patients with heterogeneous metastatic castration-sensitive prostate cancer.

Brief Report

State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2022.7835

This cohort study evaluates whether racial and ethnic disparities in incidence of triple-negative breast cancer among US women vary across states.

Research Letter

Human Papillomavirus Vaccination Prevalence and Disproportionate Cancer Burden Among US Veterans

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2022.7944

This cross-sectional study examines the rate of HPV vaccination and the number eligible for this vaccination among younger veterans and civilians.

Viewpoint

Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2022.7823

This Viewpoint discusses firearm safety guidelines among patients diagnosed with cancer and at a higher risk of suicide.

Editorial

Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer—Calling Out the “Double Standard”

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2023.0324
Comment & Response

Active Surveillance for Low-risk Papillary Thyroid Carcinoma

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2023.0003

Active Surveillance for Low-risk Papillary Thyroid Carcinoma—Reply

Abstract Full Text
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2023.0006
Correction

Change of Article Status to Open Access

Abstract Full Text
free access
JAMA Oncol. Published online March 2, 2023. doi:10.1001/jamaoncol.2023.0218
×
Baidu
map